Navigation Links
ThermoGenesis Announces Distribution Agreement for Bone Marrow Stem Cell Device
Date:9/9/2008

NEW AGREEMENT COVERS MARROWXPRESS(TM) IN KEY GLOBAL MARKETS

RANCHO CORDOVA, Calif., Sept. 9 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products and services that process and store adult stem cells, said today it has signed a distribution agreement with Celling Technologies for ThermoGenesis' MarrowXpress (MXP(TM)) product line used for isolating stem cells from bone marrow. The distribution rights are for the field of use in orthopedic intraoperative or point-of-care applications.

Celling Technologies is an innovator in the research, development and marketing of medical devices for use in regenerative medicine. Celling Technologies provides the scientific resources and technical expertise to provide services in the evolving field of stem cell therapy.

Celling Technologies will begin using the MXP to perform bone marrow stem cell separation for its existing point-of-care orthopedic procedures and perform clinical research utilizing this unique technology. The MXP offers a computerized control in the separation of stem cells from bone marrow aspirate which is first to market technology allowing surgeons to automate the steps with consistent cell separation accuracy and cryopreservation capabilities. In the field of regenerative medicine, a high concentration of stem cells delivered back to the patient offers an environment conducive to tissue regeneration.

The five-year agreement provides Celling with an initial 2 year period of exclusive distribution rights in the U.S. and non-exclusive distribution rights throughout the rest of the world, excluding Central and South America, Russia and certain Eastern European countries. ThermoGenesis will establish distri
'/>"/>

SOURCE ThermoGenesis Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThermoGenesis Reports Record Quarterly Revenues of $7.2 Million; Full Year Revenues Increase 31 Percent
2. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal 2008 on September 9, 2008
3. ThermoGenesis Names Tiffany Olson to Board of Directors
4. ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM))
5. ThermoGenesis Announces Receipt of CE Mark for MarrowXpress(TM)
6. ThermoGenesis Names Dr. Mahendra Rao to Board of Directors
7. ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health
8. ThermoGenesis Corp. Announces Voluntary Recall of Selected Lots of AXP Bag Sets
9. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
10. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2008 Results on February 6, 2008
11. ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... 2010 Halozyme Therapeutics, Inc. (Nasdaq: ... products targeting the extracellular matrix for ... today reported financial results for the third quarter ... http://photos.prnewswire.com/prnh/20100302/LA63139LOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20100302/LA63139LOGO ...
... N.J., Nov. 4, 2010 PharmaNet Development Group, Inc., ... pharmaceutical, biotechnology, generic drug and medical device companies, today ... by Company scientists at the 2010 American Association of ... from November 14 -18 at the Ernest N. Morial ...
... seventeen Texas biotechnology companies were awarded more than $35 ... part of the Qualifying Therapeutic Discovery Project Tax Credit ... and the National Institutes of Health. "The ... the ability to continue to invest resources into their ...
Cached Biology Technology:Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 2Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 3Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 4Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 5Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 6Halozyme Therapeutics Reports Third Quarter 2010 Financial Results 7PharmaNet to Present More Than 20 Posters at the 2010 American Association of Pharmaceutical Scientists Annual Meeting 2PharmaNet to Present More Than 20 Posters at the 2010 American Association of Pharmaceutical Scientists Annual Meeting 3Texas Biotech Firms Receive More Than $35 Million in Federal Grants and Credits 2Texas Biotech Firms Receive More Than $35 Million in Federal Grants and Credits 3
(Date:4/15/2014)... nanoparticle form could help reduce side effects by targeting ... scientists have developed nanoparticles that deliver one or two ... design particles that can carry any more than that ... devised a new way to build such nanoparticles, making ... drugs. In a paper published in the Journal ...
(Date:4/15/2014)... temperatures in the Congo Basin to increase by ... by greenhouse gases by half, according to a ... Belgium. , Explosive population growth and inefficient agricultural ... in Central Africa. A team of researchers from ... will affect longer-term temperatures in the region. Using ...
(Date:4/15/2014)... systems soon could be powering the forklifts used in ... with faster refueling times than ever before, courtesy of ... Carriers (HHC). , The goal of the project is ... refuel at low pressure four to five times faster ... hydrogen a competitive advantage over batteries for a big ...
Breaking Biology News(10 mins):Targeting cancer with a triple threat 2Targeting cancer with a triple threat 3Study: Deforestation could intensify climate change in Congo Basin by half 2Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 2Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 3Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 4
... intelligent prey such as monkeys which have exceptionally large ... The study, carried out by Dr Susanne Shultz, from ... Africa and South America such as the jaguar, chimpanzee, ... a small brain such as small antelope, mongooses and ...
... report that tumor cells display a dramatic reduction of ... to activate the expression of protective microRNAs in the ... issue of Cancer Cell, demonstrates that agents known to ... may function as tumor suppressors in normal cells and ...
... 90 years that cancer cells commonly display altered ... is not completely understood. Now, a new study ... reveals a functional connection between carbohydrate-driven energy production ... inhibition of a specific aspect of glucose metabolism ...
Cached Biology News:Activation of microRNA inhibits cancer gene in human cancer cells 2Researchers attack tumor cells by exploiting dependency on sugar metabolism 2
Mouse polyclonal antibody raised against a partial recombinant WRB. NCBI Entrez Gene ID = 7485...
...
Mouse monoclonal to Casein Kinase 2 beta ( Abpromise for all tested applications). entrezGeneID: 1460 SwissProtID: P13862...
Mouse monoclonal antibody raised against a partial recombinant FAAH. NCBI Entrez Gene ID = FAAH...
Biology Products: